An interventional study of FLACS +PPV+IOL + air and FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex in Macular Disease, Rhegmatogenous Retinal Detachment and Epiretinal Membrane, sponsored by Aier School of Ophthalmology, Central South University. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-20.
Sponsored by Aier School of Ophthalmology, Central South University · Not applicable, Interventional, and Treatment
Based on the progress of cataract surgery, intraocular lens development, vitreoretinal surgery and anesthesia technology in recent years, the purpose of this study is to develop a new type of more accurate and minimally invasive combined surgery for cataract and fundus diseases, and to evaluate the advantages and value of the surgery as well as related complications, so as to minimize the surgical trauma and obtain faster visual function recovery and better patient comfort. To provide new solutions for the growing demand of eye health care.
To evaluate the efficacy and complications of a new type of minimally invasive femtosecond laser assisted-cataract surgery (FLACS) combined with pars plana vitrectomy (PPV) with two-step anesthesia in the treatment of various common fundus diseases such as rhegmatogenous retinal detachment (RRD), epiretinal membrane (ERM), macular hole (MH), and vitreous opacity, complicated with cataract. It is mainly aimed at the following kinds of common fundus diseases with cataract performing PPV and cataract removal combined with monofocal or premium intraocular lens (IOL) implantation： RRD complicated with cataract: FLACS +PPV + IOL+air; ERM complicated with cataract: FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex; MH complicated with cataract: FLACS + PPV+ IOL + internal limiting membrane peeling + air; Vitreous opacity with cataract: FLACS + PPV+ IOL.
Inclusion Criteria: clinical diagnosis of following disease
Exclusion Criteria: patients with history of following condition
to evaluate the efficacy and complications of a new minimally invasive vitreoretinal surgery combined with FLACS in the treatment of rhegmatogenous retinal detachment complicated with cataract.
Procedure: FLACS +PPV+IOL + air
to evaluate the efficacy and complications of a new minimally invasive vitreoretinal surgery combined with FLACS in the treatment of epiretinal membrane complicated with cataract.
Procedure: FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex
to evaluate the efficacy and complications of a new minimally invasive vitreoretinal surgery combined with FLACS in the treatment of macular hole complicated with cataract.
Procedure: FLACS + PPV+IOL + internal limiting membrane peeling + air
to evaluate the efficacy and complications of a new minimally invasive vitreoretinal surgery combined with FLACS in the treatment of vitreous opacity complicated with cataract.
Procedure: FLACS + PPV+IOL
The procedures are combined the FLACS +PPV+IOL + air.
The procedures are combined the FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex.
The procedures are combined the FLACS + PPV+IOL + internal limiting membrane peeling + air.
The procedures are combined the FLACS + PPV+IOL.
visual acuity
final best-corrected visual acuity
Time frame: Change from baseline best-corrected visual acuity at 6 months.
complications
complications occurred during surgery or post-surgery
Time frame: through study completion, an average of 6 months.
This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aier School of Ophthalmology, Central South University